{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T21:20:46Z","timestamp":1784755246490,"version":"3.55.0"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T00:00:00Z","timestamp":1686355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T00:00:00Z","timestamp":1686355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s11864-023-01111-1","type":"journal-article","created":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T05:01:37Z","timestamp":1686373297000},"page":"948-964","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Treatment of Adult T-Cell Leukemia\/Lymphoma: Established Paradigms and Emerging Directions"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0991-5170","authenticated-orcid":false,"given":"Robert","family":"Stuver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary D.","family":"Epstein-Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,10]]},"reference":[{"key":"1111_CR1","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3389\/fmicb.2012.00388","volume":"3","author":"A Gessain","year":"2012","unstructured":"Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 Infection. Front Microbiol. 2012;3:388.","journal-title":"Front Microbiol."},{"issue":"3","key":"1111_CR2","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1128\/CMR.00063-09","volume":"23","author":"DU Gon\u00e7alves","year":"2010","unstructured":"Gon\u00e7alves DU, Proietti FA, Ribas JGR, et al. Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clin Microbiol Rev. 2010;23(3):577\u201389.","journal-title":"Clin Microbiol Rev."},{"issue":"17","key":"1111_CR3","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.1182\/blood-2012-07-445593","volume":"120","author":"LB Cook","year":"2012","unstructured":"Cook LB, Rowan AG, Melamed A, Taylor GP, Bangham CRM. HTLV-1\u2013infected T cells contain a single integrated provirus in natural infection. Blood. 2012;120(17):3488\u201390.","journal-title":"Blood."},{"issue":"1","key":"1111_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S1473-3099(19)30402-5","volume":"20","author":"G Schierhout","year":"2020","unstructured":"Schierhout G, McGregor S, Gessain A, et al. Association between HTLV-1 infection and adverse health outcomes: a systematic review and meta-analysis of epidemiological studies. Lancet Infect Dis. 2020;20(1):133\u201343.","journal-title":"Lancet Infect Dis."},{"issue":"8","key":"1111_CR5","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1182\/blood-2009-12-257410","volume":"116","author":"M Iwanaga","year":"2010","unstructured":"Iwanaga M, Watanabe T, Utsunomiya A, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood. 2010;116(8):1211\u20139.","journal-title":"Blood."},{"issue":"2","key":"1111_CR6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1089\/aid.2012.0132","volume":"29","author":"MA Demontis","year":"2013","unstructured":"Demontis MA, Hilburn S, Taylor GP. Human T cell lymphotropic virus type 1 viral load variability and long-term trends in asymptomatic carriers and in patients with human T cell lymphotropic virus type 1-related diseases. AIDS Res Hum Retroviruses. 2013;29(2):359\u201364.","journal-title":"AIDS Res Hum Retroviruses."},{"issue":"4","key":"1111_CR7","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/annonc\/mdn696","volume":"20","author":"J Suzumiya","year":"2009","unstructured":"Suzumiya J, Ohshima K, Tamura K, et al. The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia\/lymphoma: analysis of 126 patients from the International Peripheral T-Cell Lymphoma Project. Ann Oncol. 2009;20(4):715\u201321.","journal-title":"Ann Oncol."},{"key":"1111_CR8","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3389\/fmicb.2020.01124","volume":"11","author":"M Iwanaga","year":"2020","unstructured":"Iwanaga M. Epidemiology of HTLV-1 Infection and ATL in Japan: an update. Front Microbiol. 2020;11:1124.","journal-title":"Front Microbiol."},{"issue":"3","key":"1111_CR9","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/cncr.32556","volume":"126","author":"UA Shah","year":"2020","unstructured":"Shah UA, Shah N, Qiao B, et al. Epidemiology and survival trend of adult T-cell leukemia\/lymphoma in the United States. Cancer. 2020;126(3):567\u201374.","journal-title":"Cancer."},{"issue":"23","key":"1111_CR10","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1182\/blood.2019002665","volume":"135","author":"AG Rowan","year":"2020","unstructured":"Rowan AG, Dillon R, Witkover A, et al. Evolution of retrovirus-infected premalignant T-cell clones prior to adult T-cell leukemia\/lymphoma diagnosis. Blood. 2020;135(23):2023\u201332.","journal-title":"Blood."},{"issue":"1","key":"1111_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-25101-9","volume":"12","author":"M Yamagishi","year":"2021","unstructured":"Yamagishi M, Kubokawa M, Kuze Y, et al. Chronological genome and single-cell transcriptome integration characterizes the evolutionary process of adult T cell leukemia-lymphoma. Nat Commun. 2021;12(1):1\u201316.","journal-title":"Nat Commun."},{"issue":"3","key":"1111_CR12","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","volume":"79","author":"M Shimoyama","year":"1991","unstructured":"Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79(3):428\u201337.","journal-title":"Br J Haematol."},{"issue":"24","key":"1111_CR13","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1182\/blood-2015-03-632489","volume":"126","author":"H Katsuya","year":"2015","unstructured":"Katsuya H, Ishitsuka K, Utsunomiya A, et al. Treatment and survival among 1594 patients with ATL. Blood. 2015;126(24):2570\u20137.","journal-title":"Blood."},{"issue":"5","key":"1111_CR14","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1309\/2YGD1P0QCVCWBLDX","volume":"128","author":"AL Bittencourt","year":"2007","unstructured":"Bittencourt AL, Vieira MDG, Brites CR, Farre L, Barbosa HS. Adult T-cell leukemia\/lymphoma in Bahia, Brazil: analysis of prognostic factors in a group of 70 patients. Am J Clin Pathol. 2007;128(5):875\u201382.","journal-title":"Am J Clin Pathol."},{"issue":"3","key":"1111_CR15","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1200\/JCO.2008.18.2428","volume":"27","author":"K Tsukasaki","year":"2009","unstructured":"Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27(3):459.","journal-title":"J Clin Oncol."},{"issue":"Supplement 1","key":"1111_CR16","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1182\/blood-2022-168334","volume":"140","author":"B Valcarcel","year":"2022","unstructured":"Valcarcel B, Sano H, Katsuya H, et al. Clinical features, treatment patterns, and outcomes among 837 patients with adult T-cell leukemia-lymphoma in the real-world setting: a comparison of endemic regions. Blood. 2022;140(Supplement 1):1072\u20133.","journal-title":"Blood."},{"issue":"2","key":"1111_CR17","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/BF02983215","volume":"77","author":"K Tsukasaki","year":"2003","unstructured":"Tsukasaki K, Tobinai K, Shimoyama M, et al. Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109). Int J Hematol. 2003;77(2):164\u201370.","journal-title":"Int J Hematol."},{"issue":"2","key":"1111_CR18","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1046\/j.1365-2141.2001.02737.x","volume":"113","author":"Y Yamada","year":"2001","unstructured":"Yamada Y, Tomonaga M, Fukuda H, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001;113(2):375\u201382.","journal-title":"Br J Haematol."},{"issue":"34","key":"1111_CR19","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","volume":"25","author":"K Tsukasaki","year":"2007","unstructured":"Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group study JCOG9801. J Clin Oncol. 2007;25(34):5458\u201364.","journal-title":"J Clin Oncol."},{"issue":"6","key":"1111_CR20","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3816\/CLML.2010.n.084","volume":"10","author":"A Alduaij","year":"2010","unstructured":"Alduaij A, Butera JN, Treaba D, Castillo J. Complete remission in two cases of adult T-Cell Leukemia\/Lymphoma treated with Hyper-CVAD: a case report and review of the literature. Clin Lymphoma Myeloma Leuk. 2010;10(6):480\u20133.","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"3","key":"1111_CR21","doi-asserted-by":"publisher","first-page":"e408","DOI":"10.1038\/bcj.2016.21","volume":"6","author":"L Ratner","year":"2016","unstructured":"Ratner L, Rauch D, Abel H, et al. Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma. Blood Cancer J. 2016;6(3):e408.","journal-title":"Blood Cancer J."},{"issue":"2","key":"1111_CR22","doi-asserted-by":"publisher","first-page":"e4420","DOI":"10.1371\/journal.pone.0004420","volume":"4","author":"L Ratner","year":"2009","unstructured":"Ratner L, Harrington W, Feng X, et al. Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma. PLoS One. 2009;4(2):e4420.","journal-title":"PLoS One."},{"issue":"6","key":"1111_CR23","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1182\/bloodadvances.2017011106","volume":"2","author":"L Malpica","year":"2018","unstructured":"Malpica L, Pimentel A, Reis IM, et al. Epidemiology, clinical features, and outcome of HTLV-1\u2013related ATLL in an area of prevalence in the United States. Blood Adv. 2018;2(6):607\u201320.","journal-title":"Blood Adv."},{"issue":"2","key":"1111_CR24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12185-018-2455-x","volume":"108","author":"E Toriyama","year":"2018","unstructured":"Toriyama E, Imaizumi Y, Taniguchi H, et al. EPOCH regimen as salvage therapy for adult T-cell leukemia-lymphoma. Int J Hematol. 2018;108(2):167\u201375.","journal-title":"Int J Hematol."},{"issue":"12","key":"1111_CR25","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.3324\/haematol.2017.167742","volume":"102","author":"Y Maeda","year":"2017","unstructured":"Maeda Y, Nishimori H, Yoshida I, et al. Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707. Haematologica. 2017;102(12):2097\u2013103.","journal-title":"Haematologica."},{"issue":"18","key":"1111_CR26","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz N, Tr\u00fcmper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116(18):3418\u201325.","journal-title":"Blood."},{"issue":"10","key":"1111_CR27","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/cncr.20999","volume":"103","author":"MP Escal\u00f3n","year":"2005","unstructured":"Escal\u00f3n MP, Liu NS, Yang Y, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer. 2005;103(10):2091\u20138.","journal-title":"Cancer."},{"issue":"14","key":"1111_CR28","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.1002\/cncr.25147","volume":"116","author":"AA Phillips","year":"2010","unstructured":"Phillips AA, Shapira I, Willim RD, et al. A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia\/lymphoma: a multicenter clinicopathologic experience and new prognostic score. Cancer. 2010;116(14):3438\u201346.","journal-title":"Cancer."},{"issue":"10168","key":"1111_CR29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229\u201340.","journal-title":"Lancet."},{"issue":"Supplement 1","key":"1111_CR30","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood-2021-144422","volume":"138","author":"C Dittus","year":"2021","unstructured":"Dittus C, Weinstock MJ, Barnes JA, et al. Interim results of a multicenter pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide, and prednisone (BV-CHEP) for the treatment of aggressive adult T-cell leukemia\/lymphoma. Blood. 2021;138(Supplement 1):1395\u20135.","journal-title":"Blood."},{"issue":"Supplement 1","key":"1111_CR31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1182\/blood-2021-151105","volume":"138","author":"AF Herrera","year":"2021","unstructured":"Herrera AF, Zain J, Savage KJ, et al. Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone (CHEP-BV) followed by BV consolidation in patients with CD30-Expressing Peripheral T-Cell Lymphomas. Blood. 2021;138(Supplement 1):133\u20133.","journal-title":"Blood."},{"issue":"35","key":"1111_CR32","doi-asserted-by":"publisher","first-page":"4696","DOI":"10.1200\/JCO.2011.35.5578","volume":"29","author":"A Hodson","year":"2011","unstructured":"Hodson A, Crichton S, Montoto S, et al. Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia\/lymphoma. J Clin Oncol. 2011;29(35):4696\u2013701.","journal-title":"J Clin Oncol."},{"issue":"4","key":"1111_CR33","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1182\/blood.2019004045","volume":"137","author":"LB Cook","year":"2021","unstructured":"Cook LB, Phillips AA. How I treat adult T-cell leukemia\/lymphoma. Blood. 2021;137(4):459\u201370.","journal-title":"Blood."},{"issue":"Supplement 1","key":"1111_CR34","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1182\/blood-2021-151937","volume":"138","author":"K Tanimoto","year":"2021","unstructured":"Tanimoto K, Kato K, Aoki T, et al. CHOP plus sequential mogamulizumab as first-line therapy for untreated adult T-cell leukemia-lymphoma. Blood. 2021;138(Supplement 1):1393\u20133.","journal-title":"Blood."},{"issue":"5","key":"1111_CR35","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/bjh.13338","volume":"169","author":"T Ishida","year":"2015","unstructured":"Ishida T, Jo T, Takemoto S, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: A randomized phase II study. Br J Haematol. 2015;169(5):672\u201382.","journal-title":"Br J Haematol."},{"issue":"3","key":"1111_CR36","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/bjh.15123","volume":"184","author":"T Ishida","year":"2019","unstructured":"Ishida T, Jo T, Takemoto S, et al. Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: impact on allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2019;184(3):479\u201383.","journal-title":"Br J Haematol."},{"issue":"9","key":"1111_CR37","doi-asserted-by":"publisher","first-page":"5237","DOI":"10.21873\/anticanres.14527","volume":"40","author":"T Jo","year":"2020","unstructured":"Jo T, Matsuzaka K, Shioya H, et al. Mogamulizumab plus EPOCH therapy for patients with newly diagnosed aggressive adult T-cell leukemia\/lymphoma. Anticancer Res. 2020;40(9):5237\u201343.","journal-title":"Anticancer Res."},{"issue":"9","key":"1111_CR38","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.bbmt.2016.05.017","volume":"22","author":"T Sugio","year":"2016","unstructured":"Sugio T, Kato K, Aoki T, et al. Mogamulizumab treatment prior to allogeneic hematopoietic stem cell transplantation induces severe acute graft-versus-host disease. Biol Blood Marrow Transplant. 2016;22(9):1608\u201314.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"28","key":"1111_CR39","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1200\/JCO.2016.67.8250","volume":"34","author":"S Fuji","year":"2016","unstructured":"Fuji S, Inoue Y, Utsunomiya A, et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia\/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016;34(28):3426\u201333.","journal-title":"J Clin Oncol."},{"issue":"5","key":"1111_CR40","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/bmt.2015.315","volume":"51","author":"Y Inoue","year":"2016","unstructured":"Inoue Y, Fuji S, Tanosaki R, Fukuda T. Pretransplant mogamulizumab against ATLL might increase the risk of acute GVHD and non-relapse mortality. Bone Marrow Transplant. 2016;51(5):725\u20137.","journal-title":"Bone Marrow Transplant."},{"issue":"3","key":"1111_CR41","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/bmt.2015.254","volume":"51","author":"S Haji","year":"2016","unstructured":"Haji S, Kiyasu J, Choi I, et al. Administration of an anti-CC chemokine receptor 4 monoclonal antibody, mogamulizumab, before allogeneic bone marrow transplantation for adult T-cell leukemia\/lymphoma. Bone Marrow Transplant. 2016;51(3):432\u20134.","journal-title":"Bone Marrow Transplant."},{"issue":"27","key":"1111_CR42","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1200\/JCO.2010.28.0669","volume":"28","author":"A Bazarbachi","year":"2010","unstructured":"Bazarbachi A, Plumelle Y, Ramos JC, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia\/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28(27):4177\u201383.","journal-title":"J Clin Oncol."},{"issue":"4","key":"1111_CR43","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/bjh.17749","volume":"195","author":"Y Sakamoto","year":"2021","unstructured":"Sakamoto Y, Ishida T, Masaki A, et al. Clinical significance of TP53 mutations in adult T-cell leukemia\/lymphoma. Br J Haematol. 2021;195(4):571\u201384.","journal-title":"Br J Haematol."},{"issue":"1","key":"1111_CR44","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/cas.15191","volume":"113","author":"Y Sakamoto","year":"2022","unstructured":"Sakamoto Y, Ishida T, Masaki A, et al. Clinicopathological significance of CD28 overexpression in adult T-cell leukemia\/lymphoma. Cancer Sci. 2022;113(1):349\u201361.","journal-title":"Cancer Sci."},{"issue":"2","key":"1111_CR45","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/bjh.17211","volume":"192","author":"Y Sakamoto","year":"2021","unstructured":"Sakamoto Y, Ishida T, Masaki A, et al. Clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia\/lymphoma. Br J Haematol. 2021;192(2):281\u201391.","journal-title":"Br J Haematol."},{"issue":"2","key":"1111_CR46","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/bjh.17214","volume":"192","author":"S Nakahata","year":"2021","unstructured":"Nakahata S, Morishita K. The role of CD28 in adult T-cell leukaemia\/lymphoma. Br J Haematol. 2021;192(2):235\u20136.","journal-title":"Br J Haematol."},{"issue":"3","key":"1111_CR47","doi-asserted-by":"publisher","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","volume":"20","author":"SM Horwitz","year":"2022","unstructured":"Horwitz SM, Ansell S, Ai WZ, et al. T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(3):285\u2013308.","journal-title":"J Natl Compr Canc Netw."},{"issue":"3","key":"1111_CR48","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/bjh.17951","volume":"196","author":"CP Fox","year":"2022","unstructured":"Fox CP, Ahearne MJ, Pettengell R, et al. Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline. Br J Haematol. 2022;196(3):507\u201322.","journal-title":"Br J Haematol."},{"issue":"8","key":"1111_CR49","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1200\/JCO.18.00501","volume":"37","author":"LB Cook","year":"2019","unstructured":"Cook LB, Fuji S, Hermine O, et al. Revised adult T-cell leukemia-lymphoma international consensus meeting report. J Clin Oncol. 2019;37(8):677\u201387.","journal-title":"J Clin Oncol."},{"issue":"2","key":"1111_CR50","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/bmt.2015.265","volume":"51:2. 2015;51","author":"S Fuji","year":"2016","unstructured":"Fuji S, Fujiwara H, Nakano N, et al. Early application of related SCT might improve clinical outcome in adult T-cell leukemia\/lymphoma. Bone Marrow Transplant. 2016;51:2. 2015;51(2):205\u201311.","journal-title":"Bone Marrow Transplant."},{"issue":"10","key":"1111_CR51","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1038\/bmt.2014.143","volume":"49","author":"A Bazarbachi","year":"2014","unstructured":"Bazarbachi A, Cwynarski K, Boumendil A, et al. Outcome of patients with HTLV-1-associated adult T-cell leukemia\/lymphoma after SCT: a retrospective study by the EBMT LWP. Bone Marrow Transplant. 2014;49(10):1266\u20138.","journal-title":"Bone Marrow Transplant."},{"issue":"7","key":"1111_CR52","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.3324\/haematol.2017.164996","volume":"102","author":"S Fuji","year":"2017","unstructured":"Fuji S, Yamaguchi T, Inoue Y, et al. Development of a modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: possible risk-adapted management strategies including allogeneic transplantation. Haematologica. 2017;102(7):1265.","journal-title":"Haematologica."},{"issue":"8","key":"1111_CR53","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1182\/blood-2009-10-247510","volume":"116","author":"M Hishizawa","year":"2010","unstructured":"Hishizawa M, Kanda J, Utsunomiya A, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood. 2010;116(8):1369\u201376.","journal-title":"Blood."},{"issue":"5","key":"1111_CR54","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/sj.leu.2403682","volume":"19","author":"T Fukushima","year":"2005","unstructured":"Fukushima T, Miyazaki Y, Honda S, et al. Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia\/lymphoma. Leukemia. 2005;19(5):829\u201334.","journal-title":"Leukemia."},{"issue":"2","key":"1111_CR55","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1046\/j.1365-2141.2003.04054.x","volume":"120","author":"M Kami","year":"2003","unstructured":"Kami M, Hamaki T, Miyakoshi S, et al. Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia\/lymphoma. Br J Haematol. 2003;120(2):304\u20139.","journal-title":"Br J Haematol."},{"issue":"1","key":"1111_CR56","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/sj.bmt.1702731","volume":"27","author":"A Utsunomiya","year":"2001","unstructured":"Utsunomiya A, Miyazaki Y, Takatsuka Y, et al. Improved outcome of adult T cell leukemia\/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation. 2001;27(1):15\u201320.","journal-title":"Bone Marrow Transplantation"},{"issue":"9","key":"1111_CR57","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1080\/10428194.2021.1897806","volume":"62","author":"ZD Epstein-Peterson","year":"2021","unstructured":"Epstein-Peterson ZD, Ganesan N, Barker JN, et al. Outcomes of adult T-Cell leukemia\/lymphoma with allogeneic stem cell transplantation: single-institution experience. Leuk Lymphoma. 2021;62(9):2177\u201383.","journal-title":"Leuk Lymphoma."},{"issue":"20","key":"1111_CR58","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.1182\/bloodadvances.2021004932","volume":"5","author":"A Ito","year":"2021","unstructured":"Ito A, Nakano N, Tanaka T, et al. Improved survival of patients with aggressive ATL by increased use of allo-HCT: a prospective observational study. Blood Adv. 2021;5(20):4156\u201366.","journal-title":"Blood Adv."},{"issue":"8","key":"1111_CR59","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/j.bbmt.2019.05.027","volume":"25","author":"M Iqbal","year":"2019","unstructured":"\u2022 Iqbal M, Reljic T, Klocksieben F, et al. Efficacy of allogeneic hematopoietic cell transplantation in human T cell lymphotropic virus type 1-associated adult T cell leukemia\/lymphoma: results of a systematic review\/meta-analysis. Biol Blood Marrow Transplant. 2019;25(8):1695\u2013700. Meta-Analysis of allogenetic transplant in ATL.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"1\u20132","key":"1111_CR60","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3109\/10428199909145950","volume":"36","author":"K Matsushita","year":"1999","unstructured":"Matsushita K, Matsumoto T, Ohtsubo H, et al. Long-term maintenance combination chemotherapy with OPEC\/MPEC (vincristine or methotrexate, prednisolone, etoposide and cyclophosphamide) or with daily oral etoposide and prednisolone can improve survival and quality of life in adult T-cell leukemia\/lymphoma. Leuk Lymphoma. 1999;36(1\u20132):67\u201375.","journal-title":"Leuk Lymphoma."},{"issue":"22","key":"1111_CR61","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1182\/blood-2009-09-242347","volume":"115","author":"Y Takasaki","year":"2010","unstructured":"Takasaki Y, Iwanaga M, Imaizumi Y, et al. Long-term study of indolent adult T-cell leukemia-lymphoma. Blood. 2010;115(22):4337\u201343.","journal-title":"Blood."},{"issue":"26","key":"1111_CR62","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1056\/NEJM199506293322603","volume":"332","author":"PS Gill","year":"1995","unstructured":"Gill PS, Harrington W, Kaplan MH, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995;332(26):1744\u20138.","journal-title":"N Engl J Med."},{"issue":"26","key":"1111_CR63","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJM199506293322604","volume":"332","author":"O Hermine","year":"1995","unstructured":"Hermine O, Bouscary D, Gessain A, et al. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med. 1995;332(26):1749\u201351.","journal-title":"N Engl J Med."},{"issue":"42067","key":"1111_CR64","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3109\/10428190109057927","volume":"40","author":"JD White","year":"2001","unstructured":"White JD, Wharfe G, Stewart DM, et al. The combination of zidovudine and interferon aipha-2B in the treatment of adult T-cell leukemia\/lymphoma. Leuk Lymphoma. 2001;40(42067):287\u201394.","journal-title":"Leuk Lymphoma."},{"issue":"6","key":"1111_CR65","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/sj.thj.6200195","volume":"3","author":"O Hermine","year":"2002","unstructured":"Hermine O, Allard I, L\u00e9vy V, et al. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia\/lymphoma. Hematol J. 2002;3(6):276\u201382.","journal-title":"Hematol J."},{"issue":"1","key":"1111_CR66","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1742-4690-10-52","volume":"10","author":"S Kinpara","year":"2013","unstructured":"Kinpara S, Kijiyama M, Takamori A, et al. Interferon-\u03b1 (IFN-\u03b1) suppresses HTLV-1 gene expression and cell cycling, while IFN-\u03b1 combined with zidovudine induces p53 signaling and apoptosis in HTLV-1-infected cells. Retrovirology. 2013;10(1):52.","journal-title":"Retrovirology."},{"issue":"3","key":"1111_CR67","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1182\/blood-2006-01-0067","volume":"108","author":"A Datta","year":"2006","unstructured":"Datta A, Bellon M, Sinha-Datta U, et al. Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood. 2006;108(3):1021\u20139.","journal-title":"Blood."},{"issue":"1","key":"1111_CR68","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/1346-8138.12374","volume":"41","author":"K Tsukasaki","year":"2014","unstructured":"Tsukasaki K, Imaizumi Y, Tokura Y, et al. Meeting report on the possible proposal of an extranodal primary cutaneous variant in the lymphoma type of adult T-cell leukemia-lymphoma. J Dermatol. 2014;41(1):26\u20138.","journal-title":"J Dermatol."},{"issue":"15","key":"1111_CR69","doi-asserted-by":"publisher","first-page":"3961","DOI":"10.1182\/blood-2010-11-316794","volume":"117","author":"Y Sawada","year":"2011","unstructured":"Sawada Y, Hino R, Hama K, et al. Type of skin eruption is an independent prognostic indicator for adult T-cell leukemia\/lymphoma. Blood. 2011;117(15):3961\u20137.","journal-title":"Blood."},{"issue":"9","key":"1111_CR70","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O\u2019Connor","year":"2011","unstructured":"O\u2019Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182\u20139.","journal-title":"J Clin Oncol."},{"issue":"23","key":"1111_CR71","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","volume":"33","author":"OA O\u2019Connor","year":"2015","unstructured":"O\u2019Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) Study. J Clin Oncol. 2015;33(23):2492\u20139.","journal-title":"J Clin Oncol."},{"issue":"6","key":"1111_CR72","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30(6):631\u20136.","journal-title":"J Clin Oncol."},{"issue":"9","key":"1111_CR73","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1200\/JCO.2009.25.3575","volume":"28","author":"K Yamamoto","year":"2010","unstructured":"Yamamoto K, Utsunomiya A, Tobinai K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28(9):1591\u20138.","journal-title":"J Clin Oncol."},{"issue":"8","key":"1111_CR74","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","volume":"30","author":"T Ishida","year":"2012","unstructured":"Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30(8):837\u201342.","journal-title":"J Clin Oncol."},{"issue":"5","key":"1111_CR75","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/ejh.13220","volume":"102","author":"K Ishitsuka","year":"2019","unstructured":"Ishitsuka K, Yurimoto S, Tsuji Y, et al. Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma. Eur J Haematol. 2019;102(5):407\u201315.","journal-title":"Eur J Haematol."},{"issue":"10","key":"1111_CR76","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1111\/cas.13343","volume":"108","author":"T Ishida","year":"2017","unstructured":"Ishida T, Utsunomiya A, Jo T, et al. Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies. Cancer Sci. 2017;108(10):2022\u20139.","journal-title":"Cancer Sci."},{"issue":"6","key":"1111_CR77","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1001\/jamadermatol.2021.0877","volume":"157","author":"KE Hirotsu","year":"2021","unstructured":"Hirotsu KE, Neal TM, Khodadoust MS, et al. Clinical characterization of mogamulizumab-associated rash during treatment of mycosis fungoides or S\u00e9zary Syndrome. JAMA Dermatol. 2021;157(6):700\u20137.","journal-title":"JAMA Dermatol."},{"issue":"12","key":"1111_CR78","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1182\/blood.2021013341","volume":"139","author":"A de Masson","year":"2022","unstructured":"de Masson A, Darbord D, Dobos G, et al. Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients. Blood. 2022;139(12):1820\u201332.","journal-title":"Blood."},{"issue":"5","key":"1111_CR79","doi-asserted-by":"publisher","first-page":"993","DOI":"10.3324\/haematol.2018.205096","volume":"104","author":"AA Phillips","year":"2019","unstructured":"\u2022 Phillips AA, Fields PA, Hermine O, et al. Mogamulizumab versus investigator\u2019s choice of chemotherapy regimen in relapsed\/refractory adult T-cell leukemia\/lymphoma. Haematologica. 2019;104(5):993\u20131003. Randomized trial of mogamulizumab versus investigator\u2019s choice in R\/R ATL outside of Asia.","journal-title":"Haematologica."},{"issue":"7","key":"1111_CR80","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1182\/blood-2018-02-835991","volume":"132","author":"Y Sakamoto","year":"2018","unstructured":"Sakamoto Y, Ishida T, Masaki A, et al. CCR4 mutations associated with superior outcome of adult T-cell leukemia\/lymphoma under mogamulizumab treatment. Blood. 2018;132(7):758\u201361.","journal-title":"Blood."},{"issue":"5","key":"1111_CR81","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1002\/hon.3072","volume":"40","author":"Y Sakamoto","year":"2022","unstructured":"Sakamoto Y, Ishida T, Masaki A, et al. CCR7 alterations associated with inferior outcome of adult T-cell leukemia\/lymphoma under mogamulizumab treatment. Hematol Oncol. 2022;40(5):876\u201384.","journal-title":"Hematol Oncol."},{"issue":"10","key":"1111_CR82","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.3324\/haematol.2021.280352","volume":"107","author":"N Tanaka","year":"2022","unstructured":"Tanaka N, Mori S, Kiyotani K, et al. Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia\/lymphoma. Haematologica. 2022;107(10):2418\u201331.","journal-title":"Haematologica."},{"issue":"26","key":"1111_CR83","doi-asserted-by":"publisher","first-page":"3732","DOI":"10.1182\/blood.2021014468","volume":"139","author":"S Beygi","year":"2022","unstructured":"Beygi S, Duran GE, Fernandez-Pol S, et al. Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma. Blood. 2022;139(26):3732\u20136.","journal-title":"Blood."},{"issue":"2","key":"1111_CR84","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/hon.2712","volume":"38","author":"H Sakamoto","year":"2020","unstructured":"Sakamoto H, Itonaga H, Sawayama Y, et al. Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia\/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience. Hematol Oncol. 2020;38(2):162\u201370.","journal-title":"Hematol Oncol."},{"issue":"34","key":"1111_CR85","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1200\/JCO.2016.67.7732","volume":"34","author":"T Ishida","year":"2016","unstructured":"Ishida T, Fujiwara H, Nosaka K, et al. Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia\/lymphoma: ATLL-002. J Clin Oncol. 2016;34(34):4086\u201393.","journal-title":"J Clin Oncol."},{"key":"1111_CR86","doi-asserted-by":"publisher","first-page":"3","DOI":"10.23937\/2469-5696\/1410010","volume":"2","author":"AA Phillips","year":"2015","unstructured":"Phillips AA, Giddings J, Lee SM, Horwitz SM. Lenalidomide in patients with Relapsed or Refractory HTLV-1 Related Adult T cell Leukemia\/Lymphoma (ATLL). Int J Blood Res Disord. 2015;2:3.","journal-title":"Int J Blood Res Disord."},{"issue":"21","key":"1111_CR87","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1182\/blood.V120.21.2735.2735","volume":"120","author":"MA Lunning","year":"2012","unstructured":"Lunning MA, Gonsky J, Ruan J, et al. Pralatrexate in relapsed\/refractory HTLV-1 associated adult T-cell lymphoma\/leukemia: a New York City Multi-Institutional Experience. Blood. 2012;120(21):2735.","journal-title":"Blood."},{"issue":"23","key":"1111_CR88","doi-asserted-by":"publisher","first-page":"5113","DOI":"10.1182\/blood.V126.23.5113.5113","volume":"126","author":"N Mukhi","year":"2015","unstructured":"Mukhi N, Verma V, Ahmed A, et al. Romidepsin in relapsed\/refractory HTLV-1 associated adult T-cell lymphoma\/leukemia: a case series. Blood. 2015;126(23):5113.","journal-title":"Blood."},{"issue":"9","key":"1111_CR89","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1111\/cas.12735","volume":"106","author":"K Ishitsuka","year":"2015","unstructured":"Ishitsuka K, Utsunomiya A, Katsuya H, et al. A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T-cell leukemia\/lymphoma. Cancer Sci. 2015;106(9):1219\u201323.","journal-title":"Cancer Sci."},{"issue":"5","key":"1111_CR90","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3324\/haematol.10703","volume":"92","author":"K Ishitsuka","year":"2007","unstructured":"Ishitsuka K, Suzumiya J, Aoki M, et al. Therapeutic potential of arsenic trioxide with or without interferon-\u03b1 for relapsed\/refractory adult T-cell leukemia\/lymphoma. Haematologica. 2007;92(5):719\u201320.","journal-title":"Haematologica."},{"issue":"2","key":"1111_CR91","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/sj.thj.6200374","volume":"5","author":"O Hermine","year":"2004","unstructured":"Hermine O, Dombret H, Poupon J, et al. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed\/refractory adult T-cell leukemia\/lymphoma. Hematol J. 2004;5(2):130\u20134.","journal-title":"Hematol J."},{"issue":"1","key":"1111_CR92","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1158\/1078-0432.CCR-16-1022","volume":"23","author":"K Sharma","year":"2017","unstructured":"Sharma K, Janik JE, O\u2019Mahony D, et al. Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia\/lymphoma. Clin Cancer Res. 2017;23(1):35\u201342.","journal-title":"Clin Cancer Res."},{"issue":"8","key":"1111_CR93","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1111\/cas.15431","volume":"113","author":"A Utsunomiya","year":"2022","unstructured":"Utsunomiya A, Izutsu K, Jo T, et al. Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia\/lymphoma: Phase IIb results. Cancer Sci. 2022;113(8):2778.","journal-title":"Cancer Sci."},{"key":"1111_CR94","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/01.HS9.0000843940.96598.e2","volume":"6","author":"SP Iyer","year":"2022","unstructured":"Iyer SP, Sica RA, Ho PJ, et al. S262: The Cobalt-LYM Study of CTX130: a phase I dose escalation study of CD70-targeted allogeneic CRISPR-CAS9-engineered CAR T cells in patients with relapsed\/refractory (R\/R) T-cell malignancies. Hemasphere. 2022;6:163\u20134.","journal-title":"Hemasphere."},{"issue":"Supplement 1","key":"1111_CR95","doi-asserted-by":"publisher","first-page":"9448","DOI":"10.1182\/blood-2022-167888","volume":"140","author":"G Pongas","year":"2022","unstructured":"Pongas G, Toomey NL, Reis IM, et al. Safety and efficacy of belinostat trial with zidovudine plus interferon for HTLV-1 related adult T-cell leukemia-lymphoma: interim results. Blood. 2022;140(Supplement 1):9448\u20139.","journal-title":"Blood."},{"issue":"7","key":"1111_CR96","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1182\/bloodadvances.2021005948","volume":"6","author":"A Daenthanasanmak","year":"2022","unstructured":"Daenthanasanmak A, Bamford RN, Yoshioka M, et al. Triple combination of BET plus PI3K and NF-\u03baB inhibitors exhibit synergistic activity in adult T-cell leukemia\/lymphoma. Blood Adv. 2022;6(7):2346\u201360.","journal-title":"Blood Adv."},{"issue":"10","key":"1111_CR97","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1182\/blood.2021012734","volume":"139","author":"T Ishio","year":"2022","unstructured":"Ishio T, Kumar S, Shimono J, et al. Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia\/lymphoma. Blood. 2022;139(10):1541\u201356.","journal-title":"Blood."},{"issue":"1","key":"1111_CR98","doi-asserted-by":"publisher","first-page":"100913","DOI":"10.1016\/j.tranon.2020.100913","volume":"14","author":"A Daenthanasanmak","year":"2021","unstructured":"Daenthanasanmak A, Lin Y, Zhang M, et al. Enhanced efficacy of JAK1 inhibitor with mTORC1\/C2 targeting in smoldering\/chronic adult T cell leukemia. Transl Oncol. 2021;14(1):100913.","journal-title":"Transl Oncol."},{"issue":"7","key":"1111_CR99","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.3109\/10428194.2014.968780","volume":"56","author":"M Shi","year":"2015","unstructured":"Shi M, Shahsafaei A, Liu C, Yu H, Dorfman DM. Enhancer of zeste homolog 2 is widely expressed in T-cell neoplasms, is associated with high proliferation rate and correlates with MYC and pSTAT3 expression in a subset of cases. Leuk Lymphoma. 2015;56(7):2087\u201391.","journal-title":"Leuk Lymphoma."},{"issue":"7","key":"1111_CR100","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1101\/gad.186411.111","volume":"26","author":"C Simon","year":"2012","unstructured":"Simon C, Chagraoui J, Krosl J, et al. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. Genes Dev. 2012;26(7):651\u20136.","journal-title":"Genes Dev."},{"key":"1111_CR101","unstructured":"\u2022 Izutsu K, Makita S, Nosaka K, et al. An Open-Label, Single-Arm, Phase 2 Trial of Valemetostat in Relapsed or Refractory Adult T-Cell Leukemia\/Lymphoma. Blood. 2022;Sep 23(blood.2022016862.). Phase 2 trial of valemetostat in R\/R ATL, leading to approval in Japan."},{"key":"1111_CR102","doi-asserted-by":"crossref","unstructured":"Ishitsuka K, Izutsu K, Maruyama D, et al. First inhuman study of the EZH1 and EZH2 dual inhibitor valemetostat (DS-3201B) in patients with relapsed or refractory non-Hodgkin lymphoma. Hematol Oncol. 2021;39(S2):Abstract S218.","DOI":"10.1002\/hon.14_2879"},{"issue":"11","key":"1111_CR103","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/ng.3415","volume":"47","author":"K Kataoka","year":"2015","unstructured":"Kataoka K, Nagata Y, Kitanaka A, et al. Integrated molecular analysis of adult T cell leukemia\/lymphoma. Nat Genet. 2015;47(11):1304\u201315.","journal-title":"Nat Genet."},{"issue":"7","key":"1111_CR104","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1182\/blood.2021013568","volume":"139","author":"Y Kogure","year":"2022","unstructured":"Kogure Y, Kameda T, Koya J, et al. Whole-genome landscape of adult T-cell leukemia\/lymphoma. Blood. 2022;139(7):967\u201382.","journal-title":"Blood."}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-023-01111-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-023-01111-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-023-01111-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T06:22:26Z","timestamp":1689747746000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-023-01111-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,10]]},"references-count":104,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1111"],"URL":"https:\/\/doi.org\/10.1007\/s11864-023-01111-1","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,10]]},"assertion":[{"value":"5 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human and animals subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}